STAGE III PANCREATIC CANCER AJCC V8
Clinical trials for STAGE III PANCREATIC CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III PANCREATIC CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III PANCREATIC CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo targets Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in adults with advanced solid tumors that have spread or can't be removed by surgery. The main goal is to find the safest dose and check for side effects. About 66 people with cance…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 16:41 UTC
-
New hope for tough pancreatic cancer: targeted drug combo trial launches
Disease control OngoingThis early-phase trial tests a new drug, anetumab ravtansine, combined with immunotherapy (nivolumab, ipilimumab) and chemotherapy (gemcitabine) in people with advanced pancreatic cancer that has a specific marker (mesothelin). The goal is to find the safest dose and see if the c…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New drug duo targets BRCA cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—niraparib and dostarlimab—in people with breast, pancreas, or ovarian cancers that have a BRCA gene mutation and have spread or can't be removed by surgery. Niraparib blocks a DNA repair process that cancer cells rely on, wh…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New combo therapy aims to stall pancreatic cancer growth
Disease control OngoingThis study tests whether a combination of lenvatinib and pembrolizumab can help control advanced pancreatic cancer that cannot be removed by surgery. About 28 adults whose cancer has not worsened after initial treatment will receive these drugs as maintenance therapy. The goal is…
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New drug cocktail aims to starve pancreatic tumors
Disease control OngoingThis early-stage trial tests a combination of two drugs—calaspargase and cobimetinib—in about 15 people with advanced pancreatic cancer that has spread. Calaspargase works by cutting off a key nutrient that cancer cells need to grow, while cobimetinib blocks a protein that helps …
Matched conditions: STAGE III PANCREATIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC